Molecular structure of Carvedilol, CAS Number: 72956-09-3
Carvedilol (CAS 72956-09-3)
See product citations (2)
Alternate Names:
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
Application:
Carvedilol is an α1- and β-adrenergic receptor antagonist
CAS Number:
72956-09-3
Purity:
≥98%
Molecular Weight:
406.50
Molecular Formula:
C24H26N2O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Carvedilol is a AR (alpha1 and beta-adrenergic receptor) antagonist with antioxidant properties. Studies show that the receptors alpha1D-AR and alpha1B-AR have a greater affinity for Carvedilol in comparison to the receptor beta1-AR subtype. Carvedilol has been observed to block the oscillatory intracellular calcium changes induced by alpha1D-AR and alpha1B-AR, and shown to have a higher oxidative effect than Atenolol (sc-204895). The S(−) enantiomer of Carvedilol acts as a beta-blocker, and the R(+) and S (−) enantionmers both block the alpha1. Carvedilol is an inhibitor of alpha1B-AR, beta1-AR, beta2-AR and alpha1D-AR.
Carvedilol (CAS 72956-09-3) References
- Carvedilol, a beta adrenoceptor blocker with chelating properties. A copper 'superdimer' based on dimetal units. | Zoroddu, MA., et al. 2003. J Inorg Biochem. 95: 315-20. PMID: 12818802
- Effects of norepinephrine on the oxidative pentose phosphate pathway in the rat heart. | Zimmer, HG., et al. 1992. Circ Res. 71: 451-9. PMID: 1378361
- Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. | Koshimizu, TA., et al. 2004. Cardiovasc Res. 63: 662-72. PMID: 15306222
- Effect of alpha1-adrenergic receptors in cardiac pathophysiology. | Shannon, R. and Chaudhry, M. 2006. Am Heart J. 152: 842-50. PMID: 17070143
- The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. | Jonsson, G., et al. 2007. J Cardiovasc Pharmacol. 49: 27-32. PMID: 17261960
- Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. | Othman, AA., et al. 2007. AAPS J. 9: E208-18. PMID: 17614362
- Carvedilol in hypertension treatment. | Stafylas, PC. and Sarafidis, PA. 2008. Vasc Health Risk Manag. 4: 23-30. PMID: 18629377
- Distinctive effects of carvedilol in the non-infarct zone: remodelling of the ligated rat heart linked to oxidative stress. | Zhuang, XF., et al. 2009. J Int Med Res. 37: 1354-64. PMID: 19930840
- Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations. | Zielińska-Pisklak, M., et al. 2012. J Pharm Sci. 101: 1763-72. PMID: 22331650
- Combined use of ionic liquid and β-CD for enantioseparation of 12 pharmaceuticals using CE. | Zuo, L., et al. 2013. J Sep Sci. 36: 517-23. PMID: 23303483
- Effect of adrenergic blockers, carvedilol, prazosin, metoprolol and combination of prazosin and metoprolol on paracetamol-induced hepatotoxicity in rabbits. | Zubairi, MB., et al. 2014. Indian J Pharmacol. 46: 644-8. PMID: 25538338
- Dual Activity of Hydroxypropyl-β-Cyclodextrin and Water-Soluble Carriers on the Solubility of Carvedilol. | Zoghbi, A., et al. 2017. AAPS PharmSciTech. 18: 2927-2935. PMID: 28432614
- Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice. | Zidan, A., et al. 2023. Toxicol Appl Pharmacol. 465: 116448. PMID: 36921847
Inhibitor of:
β-Arrestin-1, β2-AR, β3-AR, 4930558K02Rik, alpha1B-AR, alpha1D-AR, Apoptosis, Arrestin-C, beta1-AR, beta2-AR, CBARA1 (MICU1), ERRγ, Gβ 2, GPD1L, GPR158, GPR175, HCN1, MCAD, MRAP2, Myotrophin, Olfr1, Olfr1012, Olfr1013, Olfr1018, Olfr1019, Olfr1022, Olfr1023, Olfr1030, Olfr1032, Olfr1034, Olfr1037, Olfr1039, Olfr1043, Olfr1049, Olfr1051, Olfr1056, Olfr1079, Olfr1087, Olfr1095, Olfr1100, Olfr1109, Olfr1110, Olfr1115, Olfr1507, Olfr151, Olfr224, Olfr265, Olfr393, Olfr597, Olfr668, Olfr669, Olfr67, Olfr670, Olfr671, Olfr672, Olfr675, Olfr676, Olfr677, Olfr678, Olfr679, Olfr68, Olfr681, Olfr683, Olfr684, Olfr685, Olfr686, Olfr688, Olfr689, Olfr69, Olfr690, Olfr735, Olfr736, Olfr738, Olfr765, Olfr767, Olfr768, Olfr779, Olfr827, Olfr829, Olfr883, Olfr885, Olfr887, Olfr943, Olfr944, Olfr95, Olfr951, Olfr954, Olfr959, Olfr963, Olr1076, Olr1096, Olr1104, Olr1228, Olr1425, Olr1431, Olr1433, Olr1470, Olr1488, Olr1511, Olr1517, Olr1519, Olr1520, Olr1545, Olr1546, Olr1547, Olr1559, Olr1567, Olr1569, Olr1593, Olr1602, Olr1639, Olr1640, Olr1664, Olr193, Olr210, Olr226, Olr23, Olr25, Olr251, Olr27, Olr3, Olr336, Olr358, Olr395, Olr403, Olr404, Olr415, Olr552, Olr657, Olr709, Olr713, Olr747, Olr792, Olr804, Olr831, Olr840, Olr905, OR1L1, OR2C1, phospholemman, PLB, PLC β1, Reg Iβ, RyR-2, S-100 α chain, S-antigen, TAAR9, Triadin, Troponin I-C, Troponin T-FS, V1rc3132, Visual Arrestin, Vmn1r101, Vmn1r117, Vmn1r121, Vmn1r155, Vmn1r163, Vmn2r41, Vmn2r55, Vmn2r76, VPS51, and XCR1 (X-C motif chemokine receptor 1).Activator of:
β-Arrestin-2, GRK 3, Junctional SR Marker, MafG, and NF-E2 p18.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Carvedilol, 100 mg | sc-200157 | 100 mg | $122.00 | |||
Carvedilol, 1 g | sc-200157A | 1 g | $235.00 | |||
Carvedilol, 10 g | sc-200157B | 10 g | $520.00 | |||
Carvedilol, 25 g | sc-200157C | 25 g | $979.00 | |||
Carvedilol, 100 g | sc-200157D | 100 g | $1500.00 |